PLOS Medicine: Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the U.S. and Elsewhere
Brook K. Baker, professor at Northeastern University School of Law, discusses the Trans-Pacific Partnership’s (TPP) potential impact on access to affordable medicines if its provisions are ratified, writing, “[Intellectual property (IP)] maximization in the TPP will harm access to more affordable medicines in both the U.S. and its trading partners. … Armed with knowledge about the details of the TPP’s anti-access provisions, there is still time for health advocates to convince the U.S. Congress and TPP partners that the TPP’s monopoly-enhancing measures must be rejected” (3/8).